What OpenLoop is, precisely
OpenLoop positions as white-label telehealth support services: clinician staffing (a network spanning the states), administrative services, and patient support, sold as service line items to programs that bring their own brand and stack. It also publishes one of the larger launch-a-vertical content libraries in the category, which is why founders researching almost any telehealth niche meet its name early.
The model matters more than the brand: OpenLoop is a services layer, not a storefront and not a pharmacy-economics answer. Programs plug its clinicians and back office into a funnel, checkout, and supply chain they assemble elsewhere. Judged as that layer, the offer is coherent; judged as 'a telehealth platform' in the turnkey sense, it is roughly half of one, and the missing half is the half that decides recurring-Rx margins.
What it does well
Breadth is the real strength: staffing plus admin plus support from one vendor is genuinely fewer moving parts than hiring those functions separately, and for a funded program that owns its stack, one services contract replacing three is a real simplification. The content library also reflects an organization that understands the category's questions, which is worth something in a vendor.
The buyer it serves well is specific: a program with its own storefront, funnel, and pharmacy relationships that needs credible multi-state clinical capacity without building a clinician operation. For that buyer, the shortlist is OpenLoop against Wheel and SteadyMD, and the choice runs on network fit, contract shape, and references rather than on marketing.
The 2026 diligence items
Pricing is quoted, not published, as of September 2026: service line items per engagement. That is normal for the category, and it means the burden of building the all-in per-patient number is yours; price the whole stack you will actually need (staffing plus storefront plus pharmacy plus compliance), not the entry line item.
Two public events belong in any 2026 diligence file, both restated here from public reporting rather than firsthand knowledge. First, OpenLoop disclosed a January 2026 cyberattack, and data-breach class actions followed; ask directly what changed in its security posture since. Second, a consumer lawsuit involves compounded oral GLP-1 sold through a partner brand OpenLoop powered; ask how clinical protocols and product decisions are governed across brands it serves. Neither event is a verdict, and litigation outcomes were not resolved at this writing; both are exactly the kind of thing reference calls and primary reporting exist to probe.
Third-party review coverage on the B2B marketplaces is thin for OpenLoop, as it is for most of this category, so references carry the review function: ask for programs at your volume, and run a structured reference script rather than collecting compliments.
The three questions that decide an OpenLoop evaluation: what does the full engagement cost per active patient at my volume, in writing; what changed operationally after the January 2026 incident; and who owns the pharmacy economics my program will actually live on.
Who it fits, and who should look elsewhere
Good fit: operator-led programs with an existing stack and audience that need staffed clinical capacity and back office breadth from one contract, and enterprises that want services rather than software. In those shoes, evaluate OpenLoop seriously against Wheel and SteadyMD and let references decide.
Look elsewhere if you are an audience-led brand without a stack: the storefront, funnel, retention, and medication economics all remain yours to assemble around the services, which usually means two to four more vendors and the integration burden between them. Builders wanting an API-shaped clinical layer typically shortlist Beluga Health and MD Integrations instead; brands wanting the whole business operated look at turnkey platforms.
Where EmbedCare sits, since we brought it up
EmbedCare is the operated-stack alternative: the storefront, 50-state clinicians, owned pharmacy supply, retention, and compliance run behind your brand on flat product rates fixed in a signed partner agreement, with medication included on GLP-1 programs, and a self-serve Launch tier starting at $495/mo. If the diligence question this page keeps raising (who owns the fill economics) matters to your model, that is the comparison to run, and our OpenLoop comparison page walks it dimension by dimension.
Frequently asked
- Is OpenLoop legit?
- OpenLoop is an established vendor with a real multi-state clinician network and services business, used by operating telehealth programs. Legitimacy is not the diligence question; fit and terms are: quoted pricing means you must build the all-in per-patient cost yourself, and its 2026 public record (a disclosed January 2026 security incident with follow-on litigation, and a consumer suit involving a partner brand's compounded oral GLP-1) belongs in your reference calls.
- What does OpenLoop cost?
- OpenLoop does not publish pricing as of September 2026; engagements are quoted as service line items (clinician staffing, admin, patient support). Model the whole stack you will run around it (storefront, pharmacy economics, compliance, growth) because the services contract is one layer of the cost, not the cost.
- Are there third-party OpenLoop reviews?
- Coverage on the major B2B review marketplaces is thin as of September 2026, which is true of most vendors in this category. The practical review layer is reference calls with programs at your volume, plus the public record: OpenLoop's own disclosures and the reporting around its January 2026 incident and the partner-brand GLP-1 litigation.
- What are the best OpenLoop alternatives?
- For staffing-shaped needs: Wheel and SteadyMD (the enterprise network triangle). For API-led builds: Beluga Health and MD Integrations. For the whole business operated behind your brand: EmbedCare, whose structural difference is owned pharmacy supply and flat product rates with medication included on GLP-1 programs.
- Is this review biased, since EmbedCare competes with OpenLoop?
- It is a competitor's review, disclosed as such in the first paragraph, and written to be checkable: every factual claim restates OpenLoop's public positioning or public reporting as of September 2026, with no invented scores. Verify against primary sources and references; if we have something wrong, tell us and we will correct it.
Want pricing for your program, and the Rx menu that goes with this?
The partner overview in one email; a human follows up with pricing scoped to your program.